RxDoctor Payments Data

Karen Enneking

Psychiatric/Mental Health · Mathews, VANPI 1558841940

Payments from drug & device makers

$4,098in general payments, 2019–2025

Across 194 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • AbbVie$646
  • Otsuka America Pharmaceutical, Inc.$460
  • Johnson & Johnson$329
  • Alkermes, Inc.$187
  • Vanda Pharmaceuticals Inc.$160
  • plus $652 from 10 others

What the payments were for

  • Food & beverage$4,04699%
  • Education$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,098 in reported general payments places this provider in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$18,624
Medicare patients
14
Services billed
127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate25$43,733
RexultiBrexpiprazole12$17,731
Lisdexamfetamine Dimesylate21$4,699
Lurasidone Hcl25$3,525
Atomoxetine Hcl12$2,180
Methylphenidate ErMethylphenidate Hcl18$1,630
Aripiprazole20$1,599
Doxepin Hcl21$1,296
Dextroamphetamine Sulfate11$981
Buspirone Hcl51$717
Fluvoxamine Maleate12$649
Topiramate62$564
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine32$560
Sertraline Hcl39$464
Prazosin Hcl33$329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,663$43,73325 claims
Otsuka America Pharmaceutical, Inc.Rexulti$460$17,73112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Mathews

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →